|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Dual chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin and pegylated interferon (peginterferon) is the standard of care for patients with HCV monoinfection. We investigated the effects of combination therapy in patients infected with both HBV and HCV (genotypes 1, 2, or 3).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
pubmed-author:ChaoYou-ChenYC,
pubmed-author:ChenChi-LingCL,
pubmed-author:ChenDing-ShinnDS,
pubmed-author:ChenPei-JerPJ,
pubmed-author:ChuangWan-LongWL,
pubmed-author:JengYung-MingYM,
pubmed-author:KaoJia-HorngJH,
pubmed-author:KuoHsing-TaoHT,
pubmed-author:LeeChuan-MoCM,
pubmed-author:LiaoLi-YingLY,
pubmed-author:LinChih-LinCL,
pubmed-author:LiuChen-HuaCH,
pubmed-author:LiuChun-JenCJ,
pubmed-author:LuSheng-NanSN,
pubmed-author:SuWei-WenWW,
pubmed-author:TungShui-YiSY,
pubmed-author:WuShun-ShengSS,
pubmed-author:YangSien-SingSS,
pubmed-author:YuMing-LungML
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
136
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
496-504.e3
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19084016-Adult,
pubmed-meshheading:19084016-Antibodies, Viral,
pubmed-meshheading:19084016-Antiviral Agents,
pubmed-meshheading:19084016-DNA, Viral,
pubmed-meshheading:19084016-Dose-Response Relationship, Drug,
pubmed-meshheading:19084016-Drug Therapy, Combination,
pubmed-meshheading:19084016-Female,
pubmed-meshheading:19084016-Hepacivirus,
pubmed-meshheading:19084016-Hepatitis B,
pubmed-meshheading:19084016-Hepatitis B virus,
pubmed-meshheading:19084016-Hepatitis C,
pubmed-meshheading:19084016-Humans,
pubmed-meshheading:19084016-Interferon-alpha,
pubmed-meshheading:19084016-Male,
pubmed-meshheading:19084016-Middle Aged,
pubmed-meshheading:19084016-Polyethylene Glycols,
pubmed-meshheading:19084016-Recombinant Proteins,
pubmed-meshheading:19084016-Ribavirin,
pubmed-meshheading:19084016-Taiwan,
pubmed-meshheading:19084016-Treatment Outcome,
pubmed-meshheading:19084016-Viral Interference,
pubmed-meshheading:19084016-Viral Load
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
|
|
pubmed:affiliation |
National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
